Background: Aortic stenosis (AS) is the commonest native valve lesion, affecting 43% of all patients with valvular heart disease. The optimal treatment of severe AS in cancer patients is unknown. The purpose of this study was to assess the impact of aortic valve replacement (AVR) on survival of cancer patients with severe AS.
Methods: Cancer patients with severe AS seen at our center between January 2001 and April 2007 were identified. Baseline demographics, symptoms, cancer diagnosis, laboratory data, treatment, and outcome were collected. Patient who had AVR were matched with controls who did not have AS.
Results: Out of 39,071 echocardiograms performed over the study period, 1,299 had AS (3.3%), of which 50 patients (0.13%) were identified as having severe AS. Thirteen patients (27%) underwent AVR, and 35 were managed medically. Two patients underwent valvuloplasty and were excluded. Survival was significantly longer in patients with severe AS who underwent AVR and was independent of cancer status or presence of metastases. No difference in survival was found between patients who underwent AVR and matched cancer controls. In a multivariable Cox proportional hazard regression analysis, AVR was the only significant predictor of longer survival (adjusted hazard ratio = 0.22, P = .028).
Conclusions: Cancer patients with severe AS who underwent AVR had an improved survival, regardless of cancer status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ahj.2011.03.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of STAT4 in Multiple Sclerosis patients by polymerase chain reaction and flowcytometry.
Egypt J Immunol
January 2025
Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
Multiple sclerosis (MS) is a disease of the central nervous system, characterized by progressive demyelination and inflammation. MS is characterized by immune system attacks on the myelin sheath surrounding nerve fibers. Genome-wide association studies revealed a polymorphism in the signal transducer and activator of transcription 4 (STAT4) gene that increases risk for MS.
View Article and Find Full Text PDFUse of 3D Printing Technology to Improve Lead Shield Fabrication for Electron Therapy of the Face.
Pract Radiat Oncol
January 2025
Department of Radiation Oncology, Christiana Care, Helen F. Graham Cancer Center & Research Institute, Newark, Delaware.
Superficial lesions of the face are often treated with an electron beam and surface collimation utilizing a conformal lead shield with an opening around the region of treatment (ROT). To fabricate the lead shield, an imprint of the patient face is needed. Historically, this was achieved using a laborious and time-consuming process that involved a gypsum imprinted model (GIM) of the patient topography.
View Article and Find Full Text PDFF-DCFPyL PSMA-PET/CT Versus MRI: Identifying the Prostate Cancer Region Most at Risk of Radiation Therapy Recurrence for Tumor Dose Escalation.
Pract Radiat Oncol
December 2024
Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Quebec, Canada.
Purpose: Local recurrence of prostate cancer (PCa) after radiation therapy (RT) typically occurs at the site of dominant tumor burden, and recent evidence confirms that magnetic resonance imaging (MRI) guided tumor dose escalation improves outcomes. With the emergence of prostate-specific membrane antigen (PSMA) positron emission tomography (PET), we hypothesize that PSMA-PET and MRI may not equally depict the region most at risk of recurrence after RT.
Methods And Materials: Patients with intermediate- to high-risk PCa and MRI plus PSMA-PET performed before RT were identified.
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update.
Ann Oncol
January 2025
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: The availability and affordability of safe, effective cancer therapies are core requirements for effective cancer control. Global disparities exist in access, however, yielding unequal cancer outcomes. The goal of this study was to provide updated data regarding the formulary availability, out-of-pocket costs, and accessibility of cancer medicines in countries across the full spectrum of economic development areas.
View Article and Find Full Text PDFPostoperative pancreatic fistula risk assessment using digital pathology based analyses at the parenchymal resection margin of the pancreas - Results from the randomized multicenter RECOPANC trial.
HPB (Oxford)
December 2024
Institute for Surgical Pathology, Medical Center - University of Freiburg, Germany; Core Facility for Histopathology and Digital Pathology, University of Freiburg, Germany; Faculty of Medicine, University of Freiburg, Germany. Electronic address:
Background: In pancreatic surgery Postoperative pancreatic fistula (POPF) represents the most dreaded complication, for which pancreatic texture is acknowledged as one of the strongest predictors. No consensual objective reference has been defined to evaluate the pancreas composition. The presented study aimed to mine histology data of the pancreatic tissue composition with AI assist and correlate it with clinic-pathological parameters derived from the RECOPANC study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!